Sorrento Therapeutics, Inc.
SRNE
SRNE was delisted on the 22nd of February, 2023.
46 hedge funds and large institutions have $38.6M invested in Sorrento Therapeutics, Inc. in 2017 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 14 increasing their positions, 9 reducing their positions, and 8 closing their positions.
312% more call options, than puts
Call options by funds: $103K | Put options by funds: $25K
130% more capital invested
Capital invested by funds: $16.8M → $38.6M (+$21.8M)
113% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 8
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
56% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 9
24% more funds holding
Funds holding: 37 → 46 (+9)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.83M |
| 2 |
BlackRock
New York
|
+$783K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$579K |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$562K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$293K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WCM
Wildcat Capital Management
New York
|
-$2.76M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$670K |
| 3 |
Renaissance Technologies
New York
|
-$397K |
| 4 |
ARTA
A.R.T. Advisors
New York
|
-$209K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$103K |
SRNE Hedge Fund Activity: Q4 2017 in Review
46 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Sorrento Therapeutics, Inc. (SRNE) for Q4 2017, worth a combined $38.6M — up 130% from $16.8M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new SRNE positions and 8 closed out — a net gain of 9 holders — while 14 added to existing stakes and 9 trimmed.
The largest buyer was Millennium Management, adding an estimated $1.83M. The largest seller was Wildcat Capital Management, cutting an estimated $2.76M.
- 46 institutional investors held Sorrento Therapeutics, Inc. (SRNE) as of Q4 2017, up from 37 in Q3 2017.
- Funds reported $38.6M of Sorrento Therapeutics, Inc. stock for Q4 2017, up 130% quarter-over-quarter.
- 17 funds opened new Sorrento Therapeutics, Inc. positions in Q4 2017 and 8 closed out, a net change of +9 holders.
- The largest Sorrento Therapeutics, Inc. buyer in Q4 2017 was Millennium Management, an estimated $1.83M added.
- The largest Sorrento Therapeutics, Inc. seller in Q4 2017 was Wildcat Capital Management, an estimated $2.76M sold.
Based on aggregated 13F filings for Q4 2017.